TSA-II NeuroSensory Analyzer and PATHWAY (ATS / CHEPS) systems enable clinicians to evaluate specific components of the nociceptive system, including pain-mediating unmyelinated C-fibers. These advanced clinical tools allow physicians to investigate and correlate pain with both central and peripheral nervous system abnormalities and diagnose neuropathic pain syndromes.
Much research in chronic pain strengthens the growing trend to recognize and mandate pain as the “fifth vital sign.” This is due to a limited understanding of the basic mechanisms of pain. Without a detailed diagnosis that reflects the underlying pathophysiology of pain, treatment is often random guesswork. Understanding the basic pathophysiology of pain can help physicians provide optimal and medically justifiable treatment.
QST and Advanced QST offer quantitative data that enables physicians to individualize and balance the diverse approaches, to reach an optimal treatment modality in complex chronic pain. By understanding the cause, physicians have the tools they need to effectively treat patients with better pain relief.